Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 11/20 | 0.37 |
| ▸ | CA2 | P00918 | 11/20 | 0.37 |
| ▸ | CA12 | O43570 | 9/20 | 0.37 |
| ▸ | CA9 | Q16790 | 9/20 | 0.37 |
| ▸ | CA4 | P22748 | 7/20 | 0.37 |
| ▸ | CA7 | P43166 | 5/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 5/20 | 0.37 |
| ▸ | CA3 | P07451 | 3/20 | 0.37 |
| ▸ | CA6 | P23280 | 3/20 | 0.37 |
| ▸ | CA5A | P35218 | 3/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625219 | 0.93 | PTGER4 (0.42) | PTGER4NTRK1NTRK2CNR2 | |
| SCHEMBL1624648 | 0.92 | PTGER4 (0.45) | PTGER4NTRK1NTRK2CNR2 | |
| SCHEMBL1624588 | 0.90 | PTGER4 (0.43) | PTGER4NTRK1NTRK2CNR2 | |
| SCHEMBL1625002 | 0.89 | PTGER4 (0.42) | PTGER4NTRK1NTRK2CNR2 | |
| SCHEMBL1626179 | 0.88 | PTGER4 (0.42) | PTGER4NTRK1NTRK2CNR2 | |
| SCHEMBL1626993 | 0.86 | PTGER4 (0.41) | PTGER4NTRK1NTRK2CNR2 | |
| SCHEMBL1623250 | 0.86 | PTGER4 (0.41) | PTGER4NTRK1NTRK2CNR2 | |
| SCHEMBL1624406 | 0.86 | PTGER4 (0.43) | PTGER4NTRK1NTRK2CNR2 | |
| SCHEMBL1625211 | 0.86 | PTGER4 (0.44) | PTGER4NTRK1NTRK2CNR2 | |
| SCHEMBL1626185 | 0.86 | PTGER4 (0.44) | PTGER4NTRK1NTRK2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928119-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7148234-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | PTGER4 1/4885CA1 4549/4885CA2 4405/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885CA1 2963/4885CA2 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.